Neoadjuvant Immunotherapy Using PD-1 Inhibitors for Resectable Stage III Cutaneous Melanoma—Different Outcomes Between Patients With Lymph Node and In-transit Metastases
- DOI
- 10.1097/sla.0000000000007177
- Published
- 2026-07-29
- Container
- Annals of Surgery
- Publisher
- Ovid Technologies (Wolters Kluwer Health)
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1097/sla.0000000000007177,
title = {Neoadjuvant Immunotherapy Using PD-1 Inhibitors for Resectable Stage III Cutaneous Melanoma—Different Outcomes Between Patients With Lymph Node and In-transit Metastases},
author = {Ellen Krabbe and Anne Huibers and Ana Carneiro and Karolin Isaksson and Karl Björkström and Braslav Jovanovic and Antonios Valachis and Gustav J. Ullenhag and Hildur Helgadottir and Lars Ny and Axel Nelson and Roger Olofsson Bagge},
year = {2026},
journal = {Annals of Surgery},
doi = {10.1097/sla.0000000000007177},
url = {https://doi.org/10.1097/sla.0000000000007177}
}RIS
TY - JOUR TI - Neoadjuvant Immunotherapy Using PD-1 Inhibitors for Resectable Stage III Cutaneous Melanoma—Different Outcomes Between Patients With Lymph Node and In-transit Metastases AU - Ellen Krabbe AU - Anne Huibers AU - Ana Carneiro AU - Karolin Isaksson AU - Karl Björkström AU - Braslav Jovanovic AU - Antonios Valachis AU - Gustav J. Ullenhag AU - Hildur Helgadottir AU - Lars Ny AU - Axel Nelson AU - Roger Olofsson Bagge PY - 2026 JO - Annals of Surgery DO - 10.1097/sla.0000000000007177 UR - https://doi.org/10.1097/sla.0000000000007177 ER -
APA
Krabbe, E., Huibers, A., Carneiro, A., Isaksson, K., Björkström, K., Jovanovic, B., Valachis, A., Ullenhag, G. J., Helgadottir, H., Ny, L., Nelson, A., & Bagge, R. O. (2026). Neoadjuvant Immunotherapy Using PD-1 Inhibitors for Resectable Stage III Cutaneous Melanoma—Different Outcomes Between Patients With Lymph Node and In-transit Metastases. Annals of Surgery. https://doi.org/10.1097/sla.0000000000007177
Source records
- crossref · retrieved 2026-09-26T15:58:13.097Z